OTCM
STEX
Market cap11mUSD
Oct 19, Last price
0.37USD
1D
-0.80%
1Q
-54.15%
Jan 2017
-97.12%
IPO
-98.84%
Name
BioSig Technologies Inc
Chart & performance
P/E
—
P/S
290.62
EPS
—
Div yield, %
—
Shs. 5Y
132.44%
Rev. 5Y
%
Revenues
40k
+122.22%
Net income
-10m
L-64.43%
CFO
-5m
L-72.52%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BioSig Technologies, Inc., along with its subsidiaries, operates as a medical technology enterprise. Its core innovation is the PURE EP (precise uninterrupted real-time evaluation of electrograms electrophysiology) system. This proprietary signal processing platform, merging specialized hardware and software, tackles well-known difficulties in electrophysiological signal acquisition, empowering electrophysiologists to instantaneously view and analyze vital cardiac signals. The system further enhances the collection of intracardiac signals and diagnostic data crucial for atrial fibrillation procedures. Moreover, it is specifically engineered to overcome persistent obstacles that traditionally slow down and complicate cardiac catheter ablation. BioSig also holds a research agreement with the University of Minnesota, targeting the development of new treatments for sympathetic nervous system disorders. Additionally, it has a strategic partnership with the Mayo Foundation for Medical Education and Research, focused on creating an advanced AI and machine learning software solution tailored for its PURE EP platforms. Established in 2009, BioSig Technologies, Inc. is headquartered in Westport, Connecticut.
Key people
Mitchell Williams
Chief Investment Officer · since 2025
Interim Chief Financial Officer, Principal Accounting Officer, Vice President - Finance · since 2024
Karl Mcphie
Chief Executive Officer, Director · since 2025
Donald Browne
Independent Director · since 2024
Kevin Gopaul
Independent Director · since 2025
Morgan Lekstrom
Independent Chairman of the Board · since 2025
Anthony Marciano
Independent Director · since 2026
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||